Home

GEOFFREY F COX

CIK 1021014 · Interim CEO · last filed 2019-06-14

GEOFFREY F COX is an Interim CEO who has filed 42 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for VXRT, was dated Jun 14, 2019. Across all open-market trades the lifetime net is +$120.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $509.9K across reported positions. 10 SEC filings were submitted jointly with QLT INC/BC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$509.9K

Companies

8

Total Filings

42

Lifetime Open-Market Net

$120.2K

Filer Profile

Reported Address
175 CROSSING BOULEVARD
FRAMINGHAM, MA 01702
State of Incorporation
MA
Related Filers
QLT INC/BC — 10 joint filings, latest 2016-12-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Vaxart, Inc. (VXRT) Delisted Director — $0.32 — $0 1 2019-06-14
AVIR Director — $5.83 — $0 2 2017-05-22
IMMUNOMEDICS INC (IMMU) Delisted Director — — — $0 1 2017-01-10
NOVELION THERAPEUTICS INC. (NVLN) Delisted Director — — — $0 1 2016-12-27
QLTI Interim CEO 18,500 $27.56 $509.9K $0 7 2016-06-21
Vaxart, Inc. (BOTA) Delisted Director — — — $0 3 2015-08-13
Vaxart, Inc. (NABI) Delisted Non-Executive Chairman 4,280 — — $10.0K 5 2011-05-27
GTC BIOTHERAPEUTICS INC (GTCB) Delisted President, CEO and Chairman 80,811 — — $110.2K 21 2009-11-13

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-06-14 Vaxart, Inc. (VXRT) Delisted Grant (A) — $0 EDGAR
2017-05-22 AVIR Grant (A) — $0 EDGAR
2017-01-10 IMMUNOMEDICS INC (IMMU) Delisted Grant (A) — $0 EDGAR
2016-12-27 NOVELION THERAPEUTICS INC. (NVLN) Delisted Grant (A) — $0 EDGAR
2016-12-08 — Grant (A) — $0
2016-06-21 QLTI Grant (A) — $0 EDGAR
2016-05-13 AVIR Grant (A) — $0 EDGAR
2015-08-13 Vaxart, Inc. (BOTA) Delisted Grant (A) — $0 EDGAR
2015-07-01 QLTI Exer (M) +72,500 $262.5K EDGAR
2015-06-09 QLTI Exer (M) +4,000 $0 EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.